Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | EPHX1 | P07099 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.45 |
| ▸ | ANPEP | P15144 | 2/20 | 0.44 |
| ▸ | ERAP2 | Q6P179 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5766448 | 0.79 | EPHX2 (0.51) | EPHX2ALDH1A1TDP1EPHX1HPGD | |
| SCHEMBL6439424 | 0.76 | AGER (0.42) | EPHX2ALDH1A1TDP1MEN1KMT2A | |
| SCHEMBL7798099 | 0.76 | EPHX2 (0.62) | EPHX2ALDH1A1EPHX1MEN1KMT2A | |
| SCHEMBL27571365 | 0.75 | NPC1 (0.47) | EPHX2TDP1RAB9A | |
| SCHEMBL8072282 | 0.73 | EPHX2 (0.56) | EPHX2ALDH1A1TDP1EPHX1MEN1 | |
| SCHEMBL1008399 | 0.73 | POLB (0.54) | ALDH1A1MEN1KMT2ARAB9A | |
| Cyclohexylamine SCHEMBL5767389 | 0.71 | ALPI (0.45) | EPHX2ALDH1A1TDP1EPHX1MEN1 | |
| Cyclohexylamine SCHEMBL6437917 | 0.71 | ALPI (0.45) | EPHX2ALDH1A1TDP1EPHX1MEN1 | |
| SCHEMBL29069392 | 0.71 | GAA (0.57) | EPHX2ALDH1A1 | |
| SCHEMBL29069391 | 0.71 | GAA (0.57) | EPHX2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050245764-A1 | Process for producing optically active 2-substituted carboxylic acid | KANEKA CORPORATION (JP) | 2005-11-03 | — | — | US | disclosed |
| EP-1422215-A1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE 2-SUBSTITUTED CARBOXYLIC ACID | KANEKA CORPORATION (JP) | 2004-05-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245764-A1 | Process for producing optically active 2-substituted carboxylic acid | CA2, UACA, ATIC | EPHX2 485/4885ALDH1A1 981/4885TDP1 4766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.